FDA leaders from CDER and CBER are scheduled to meet with key industry groups including BIO and PhRMA to discuss the reauthorization of the Prescription Drug User Fee Act (PDUFA). These discussions will shape the regulatory environment affecting drug approval processes and industry commitments over the coming years. The outcome will impact timelines, fees, and resource allocation critical to biotechnology and pharmaceutical sectors.